|
|
Medical Tests – Manufacturing Certainty in Pseudo [fake] Science
This article was provided courtesy of Dr. Leonard G. Horowitz and Tetrahedron Publishing Group; written by David Crowe, June 23, 2003.
"Tests
indicate that you have a 90% chance of being infected with a deadly virus.
There is a 50% probability that it will cause disease within the next 10 years,
and a possibility that it never will. If you take the drugs that I offer, there
is a significant risk that you will experience a great decline in your quality
of life, and a possibility that the drugs will kill you."
Although
it might be the truth, you are unlikely to hear a doctor saying this, because
neither the doctor nor the patient can deal with the uncertainty that it
admits.
Technology
is the practical application of science, and one of the major distinctions is
its need for certainty. Studying semiconductor physics can be a beautiful
thing, but it remains pure science until a discovery results in products that
can be reliably manufactured and used.
Biological systems, especially human
beings, are far more complex and less predictable than inorganic systems.
Medicine, being the practical application (technology) of human biologic
science, requires a high degree of certainty before new discoveries can be
applied.
Unfortunately, a feeling of certainty can be manufactured, and there are many motivations to do so.
On October
12, 2001, a CDC scientist phoned then mayor of New York City, Rudolph Giuliani,
to tell him that, "with a high degree of probability", a sample of
skin from an NBC employee in Manhattan was positive for cutaneous
anthrax.
The CDC scientist had this confidence, because he had confidence in a
test that a colleague had previously developed. But this was not good enough
for Giuliani. "Don't give me that stuff. Is it anthrax or not?" An
unqualified "Yes" from the CDC scientist kicked off the anthrax
crisis in New York City. [Altman, 2001]
A
"No," under the circumstances, would have been almost impossible. The
consequences for the CDC and Giuliani, if others had later confirmed anthrax,
would have been devastating to their careers. While reporters might have questioned
the accuracy of a "No," there was not a whisper of dissent on the
"Yes."
Medical
tests are a common way to manufacture certainty. A test usually measures a
'surrogate marker' for a condition, something that is otherwise invisible, or
at least much more difficult, expensive and time consuming to find directly.
A nicely packaged test can instill confidence and, in a
sense, create a disease when a positive test result is accepted without any
symptoms being present.
An HIV
test is perhaps the best example. A positive test is devastating to most
people, particularly those who are outside the traditional risk groups and
completely unprepared. Feelings of doom come, not surprisingly, even to those
who are perfectly healthy at the time of the test [Gala, 1992].
Desperate
feelings lead to desperate actions, and, for HIV, the desperate action is to
take AIDS medications. Antiviral drugs have fatal side effects, and even those
who avoid that are likely to experience a destruction of their quality of life,
even if they were completely healthy at the time of the test [Goodman, 2002].
Obviously,
the doctor and patient must feel certain that tests are accurate. If the
patient was told that there was only a 90% certainty that the test was accurate
they might be much less likely to take medications carrying such risks.
The almost
universal impression among scientists, the media, governments and the general
public that HIV tests are accurate enough to stake your life on is, strangely
enough, so strong because there is no absolute measure against which the tests
can be validated. Instead of accepting this as uncertainty over whether the
tests are meaningful, it is accepted as lack of proof that they are not highly
accurate.
All that
Robert Gallo's and Luc Montagnier's research teams
found was a high correlation between their antibody tests and AIDS. People with
AIDS had a high probability (88% in the case of Gallo [Sarngadharan,
1984]) of testing positive, and people without AIDS had a very low probability
of testing positive.
A huge conceptual leap over a chasm of uncertainty was to
conclude from this evidence that a positive test in a healthy person proved
they had a condition that would inevitably kill them.
The
science of HIV testing has progressed since then, but only in technological
ways (such as the use of monoclonal antibodies); the original logical
uncertainties still exist.
Almost every scientific paper concerning HIV tests
still uses antibody tests as the "gold standard." This is unusual
because antibody tests, even if one ignores the possibility of cross reactions,
can only prove past exposure to a virus, not current infection.
HIV
antigen tests, which are more direct, are only positive in about half the
people who are HIV-antibody positive [McKinney, 1991; Semple,
1991]. This finding is explained away through an immune reaction which masks
the antigen. But, this implies that the HIV infection is conquered, which is
not compatible with the notion that HIV infection is incurable.
Virus
cultivation, often erroneously called 'isolation' is an even older method than
antibody testing for HIV, but apart from being time consuming, expensive and
difficult to perform, it also is negative quite frequently, and a positive
antibody test usually trumps a negative culture [Layon,
1986] (and vice-versa [Eur Coll,
1991; Imagawa, 1989]).
The major
new test since the early days of AIDS is the Polymerase Chain Reaction, often
called 'viral load' when used for HIV tests. This also takes a back seat to
antibody tests [Roche, 1996], likely because it is so
ultra-sensitive that the risk of a false positive is high.
Furthermore,
detecting a snippet of genetic material (RNA or DNA, depending on the type of
test) does not prove that the entire genome is present, and obviously does not
prove that infectious virus particles are present. This test is particularly
uncertain because the genetic material does not come from purified virus.
Even
accepting the test's ability to specifically detect HIV DNA or RNA, one
research team estimated that only one infectious virus particle was present for
every 60,000 measured by viral load! [Piatak, 1993;
Roche, 1996]
All HIV
tests are indirect, even virus 'isolation' by culturing. Consequently, some
'gold standard' is necessary to validate them [Cleary, 1987; Abbott, 1997;
Meyer, 1987; Daar, 2001; Papadopulos,
2003].
The only standard that is reasonable for a virus is actual purification
direct from body fluids of people who are HIV infected and the inability to
purify from people who are not. Virus purification would allow the proper
characterization of the virus, so that antigens, antibodies, DNA and RNA that
are generally believed to be from HIV could be proven to be from HIV (or not).
Without a
'gold standard' for HIV infection the only way to validate the test is by
repeating the test or by comparing it against different (also unvalidated) tests. This can establish the reproducibility
of the test, but not its specificity (ability to react with the target and
therefore avoid false positives) or sensitivity (ability to react to cases of
infection and therefore avoid false negatives).
US army
researchers claimed that the specificity of HIV antibody tests was only 1 false
positive out of 135,187 tests [Burke, 1988]. However, although they claimed to
have established a high specificity for antibody tests, they were actually
verifying only reproducibility, and the researchers did not actually prove that
the 15 people from this low risk population who were deemed to have had true
positive tests actually had the virus in them.
Modern
diseases that are blamed on a virus are often little more than the test because
the disease can exist without clinical symptoms. There is an average of 10
years between becoming HIV positive and the first signs of AIDS in both rich
countries [Munoz, 1995] and poor [Morgan, 2002]. In that time the HIV test is
the only sign that anything is wrong.
Worse yet, a low CD4 cell count test can
result, in the United States, in a diagnosis of AIDS (not just HIV infection),
again without any clinical symptoms. But even without symptoms a diagnosis of
HIV infection or AIDS will still often result in treatment because of
everyone's confidence in the tests.
Other
viral diseases might not have a long incubation period, but the test still
plays the prime role in defining the condition. West Nile disease, for example,
is associated with no illness in the majority of people who test positive, and
serious illness in only about 1 out of 150 [Petersen, 2002]. The symptoms, when
they do occur, are indistinguishable from many other viral diseases [CDC,
2002].
This has not resulted in a call to question the accuracy of the tests.
Instead, the certainty that any symptoms found along with a positive test are
due to the virus is so great that when the symptoms are uncharacteristic
scientists want to add them to the definition, rather than to ask whether the
tests are accurate and whether presence of a virus is proof of pathogenicity [Glass, 2002; Leis, 2002]
One of the
strange phenomena with HIV and AIDS science was overwhelming feeling of
certainty that crept over scientists in the mid-1980's.
Only 3.4% of papers in 1984 associated a reference to Gallo's original 1984
papers on HIV (HTLV-III) with "explicit and unqualified" assertions
that HIV caused AIDS but this increased to 25% in 1985 and 62% in 1986, even
when these papers were referenced alone. [Epstein, 1996]
Kary
Mullis, who received the 1993 Nobel for Chemistry (ironically because of his
invention of the Polymerase Chain Reaction) has asked many scientists for a set
of references that constitute proof that HIV causes AIDS [Duesberg,
1996] and has not yet received them. Yet, even without this proof being written
down in a scientific paper, certainty still reigns.
SARS
illustrates how quickly researchers can manufacture certainty today. The
mainstream media (which claim to be "responsible") have ensured us
that everyone knows SARS is
caused by a Coronavirus.
Reports from Dr. Frank
Plummer, one of Canada's top virologist, that a
diminishing percentage of patients (30% by mid-April) are testing positive do
not dissuade them from this belief [Altman, 2003]. Everyone knows that
there is no possible explanation for all the patients having some connection
with the original cases other than an infectious agent, even though for some
outbreaks there was no solid connection, and tautologically, the epidemiologic
connection is supposed to be present before diagnosing SARS (as opposed to some
other disease with similar symptoms).
And, everyone also knows that
there is no other explanation for the severity of the disease, certainly not
the new phenomenon of aggressive prescription of steroids and the antiviral ribavirin that occurred as the fear of the outbreak spread
[Koren, 2003].
What
HIV/AIDS science took two years to do, SARS science took only two months to
accomplish. I predict that a Coronavirus test will
soon become part of the SARS case definition, which will immediately create a
100% correlation between the Coronavirus and SARS
symptoms. Just as with AIDS, the same symptoms without a positive test will be
another disease, and not taken nearly as seriously.
People
demand simple answers to complex problems and modern medical science delivers.
We are told that tests are highly accurate, that drugs will cure conditions or,
if that is not possible, that they are the best bet.
We are told that
environmental conditions play little role in modern, emerging diseases.
Alternative therapy is scoffed at because it has not been 'proven' effective
through randomized, placebo-controlled clinical trials.
The
fundamental reason why this confidence game continues to be played is because
of human laziness. It is much easier to learn about science by rote than by
examining evidence and making up one's own mind. Obviously, not every
pronouncement on science can be taken seriously, so the status of a person or
publisher becomes the way to distinguish between "good science" and
"junk science."
Many
people do not believe that they have the ability to understand scientific
papers. The media, even most science reporters, are much more productive if
they also adopt this attitude. Among scientists, there is a hierarchy which is
constructed from the anonymous peer review system for publication and grant
support.
This allows longer-serving officers of science to anonymously subvert
the attempts of younger scientists (and outsiders) to reappraise current
dogmas, by denying them the ability to publish and obtain research funding.
Further Reading
-
[Abbott,
1997] Human Immunodeficiency Virus Type 1 HIVAB HIV-1 EIA. Abbott Laboratories.
1997 Jan.
-
[Altman,
2001] Altman LK. When everything changed at the CDC. NY Times. 2001 Nov 13.
-
[Altman,
2003] Altman LK. Virus Proves Baffling, Turning Up in Only 40% of a Lab's Test
Cases. NY Times. 2003 Apr 24.
-
[Burke,
1988] Burke DS et al. Measurement of the false positive rate in a screening
program for human immunodeficiency virus infections. N Engl
J Med. 1988; 319(15): 961-4.
-
[CDC,
2002] Encephalitis or Meningitis, Arboviral (includes
California serogroup, eastern equine, St. Louis,
western equine, West Nile, Powassan): 2001 Case
Definition. CDC. 2002 Sep 6.
-
[Cleary,
1987] Cleary PD et al. Compulsory premarital screening for the human
immunodeficiency virus: Technical and public health considerations. JAMA. 1987;
258: 1757-62.
-
[Daar, 2001] Daar ES et al.
Diagnosis of primary HIV-1 infection. Ann Intern Med. 2001 Jan 2; 134(1).
-
[Duesberg, 1996] Duesberg P et al.
Inventing the AIDS virus. Regnery. 1996.
-
[Epstein,
1996] Epstein S. Impure science: AIDS, activism, and the politics of knowledge.
University of California Press. 1996.
-
[Eur Collab, 1991] European
Collaborative Study. Children born to women with HIV-1 infection: natural
history and risk of transmission. Lancet. 1991; 337: 253-60.
-
[Gala,
1992] Gala C et al. Risk of deliberate self-harm and factors associated with
suicidal behaviour among asymptomatic individuals with human immunodeficiency
virus infection. Acta Psychiatr
Scand. 1992 Jul; 86(1): 70-5. Also Serunkuuma R.
Living with HIV/AIDS: a personal testimony. AIDS Health Promot
Exch. 1994; (3):7. Also Call to explore HIV test and
suicide link. Nurs Times. 1994; 90(30):9.
-
[Glass,
2002] Glass JD et al. Poliomyelitis Due to West Nile Virus. N Engl J Med. 2002 Oct 17.
-
[Goodman,
2002] Goodman L. The problem with protease. Poz. 2002
Sep; 33-8.
-
[Imagawa, 1989] Imagawa DT et al.
Human immunodeficiency virus type I infection in homosexual men who remain seronegative for prolonged periods. N Engl
J Med. 1989 Jun 1; 320(22): 1458-62.
-
[Koren, 2003] Koren G et al. Ribavirin in the treatment of SARS: A new trick for an old
drug? CMAJ. 2003 May 13; 168(10): 1289-92.
-
[Layon, 1986] Layon J et al.
Acquired immunodeficiency syndrome in the United States: a selective review. Crit Care Med. 1986; 14(9): 819-27.
-
[Leis,
2002] Leis AA et al. A poliomyelitis-like syndrome from West Nile Virus
infection. N Engl J Med. 2002 Oct 17.
-
[McKinney,
1991] McKinney RE et al. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency
virus disease. N Engl J Med. 1991 Apr 11; 324(15):
1018-25.
-
[Meyer,
1987] Meyer KB et al. Screening for HIV: can we afford the false positive rate?
N Engl J Med. 1987; 317(4): 238-41.
-
[Morgan,
2002] Morgan D et al. HIV-1 infection in rural Africa: is there a difference in
median time to AIDS and survival compared with that in industrialized
countries? AIDS. 2002; 16: 597-603.
-
[Muñoz, 1995] Muñoz A et al.
Long-term survivors with HIV-1 infection; incubation period and longitudinal
patterns of CD4+ lymphocytes. J Acquir Immune Defic Syndr. 1995 Apr 15; 8(5):
496-505.
-
[Papadopulos-Eleopulos, 2003] Papadopulos-Eleopulos
E et al. High rates of HIV seropositivity in Africa -
alternative explanation. Int J STD AIDS. 2003; 14:
426.
-
[Petersen,
2002] Petersen LR et al. West Nile virus: a primer for the clinician. Ann
Intern Med. 2002 Aug 6; 137(3): 173-9.
-
[Piatak, 1993] Piatak M Jr et al. High levels of HIV-1 in plasma during all stages
of infection determined by competitive PCR. Science. 1993 Mar 19; 259: 1749-54.
-
[Roche,
1996] Amplicor HIV-1 Monitor Test. Roche. 1996.
-
[Sarngadharan, 1984] Sarngadharan
MG et al. Antibodies Reactive with Human T-Lymphotropic
Retroviruses (HTLV-III in the Serum of Patients with AIDS). Science. 1984 May
4; 224: 506-8.
-
[Semple, 1991] Semple M et al.
Direct measurement of viraemia in patients infected
with HIV-1 and its relationship to disease progression and zidovudine
therapy. J Med Virol. 1991; 35: 38-45.
Also See:
|